CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 564 enrolled
Drug / intervention
Glycopyrronium Topical Wipesdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02553798
NCT02553798Phase 3Completed
CompareCT.gov

An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Journey Medical Corporation·interventional·Posted Sep 18, 2015·Updated Aug 25, 2021

In Brief

A Phase 3 clinical trial evaluating Glycopyrronium Topical Wipes for Hyperhidrosis. Completed, enrolled 564 participants across 48 sites in 2 countries.

Detailed Summary

This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis
CountriesGermany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 18, 2015
Enrollment StartAug 1, 2015
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.8 years ago

Interventions

Glycopyrronium Topical Wipesdrug

Glycopyrronium Topical Wipes